Podcasts about Fujifilm

What happens when the creator of Stack Overflow decides he's going to take on rural poverty with a guaranteed minimum income—and bankrolls it himself? Find out why Jeff Atwood believes AI and philanthropy might matter more to the American dream than any new software ever could. Hegseth gives Anthropic CEO until Friday to back down in AI safeguards fight Musk's xAI and Pentagon reach deal to use Grok in classified systems Anthropic Accuses Chinese Companies of Siphoning Data From Claude How will OpenAI compete? — Benedict Evans My first vibe coding project! Anthropic Links AI Agent With Tools for Investment Banking, HR THE 2028 GLOBAL INTELLIGENCE CRISIS QuitGPT is going viral — 700,000 users are reportedly ditching ChatGPT for these AI rivals IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat OpenAI's first ChatGPT gadget could be a smart speaker with a camera ChatGPT spits out surprising insight in particle physics "Clavicular was mid jestergooning when a group of Foids came and spiked his Cortisol levels

What happens when the creator of Stack Overflow decides he's going to take on rural poverty with a guaranteed minimum income—and bankrolls it himself? Find out why Jeff Atwood believes AI and philanthropy might matter more to the American dream than any new software ever could. Hegseth gives Anthropic CEO until Friday to back down in AI safeguards fight Musk's xAI and Pentagon reach deal to use Grok in classified systems Anthropic Accuses Chinese Companies of Siphoning Data From Claude How will OpenAI compete? — Benedict Evans My first vibe coding project! Anthropic Links AI Agent With Tools for Investment Banking, HR THE 2028 GLOBAL INTELLIGENCE CRISIS QuitGPT is going viral — 700,000 users are reportedly ditching ChatGPT for these AI rivals IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat OpenAI's first ChatGPT gadget could be a smart speaker with a camera ChatGPT spits out surprising insight in particle physics "Clavicular was mid jestergooning when a group of Foids came and spiked his Cortisol levels

What happens when the creator of Stack Overflow decides he's going to take on rural poverty with a guaranteed minimum income—and bankrolls it himself? Find out why Jeff Atwood believes AI and philanthropy might matter more to the American dream than any new software ever could. Hegseth gives Anthropic CEO until Friday to back down in AI safeguards fight Musk's xAI and Pentagon reach deal to use Grok in classified systems Anthropic Accuses Chinese Companies of Siphoning Data From Claude How will OpenAI compete? — Benedict Evans My first vibe coding project! Anthropic Links AI Agent With Tools for Investment Banking, HR THE 2028 GLOBAL INTELLIGENCE CRISIS QuitGPT is going viral — 700,000 users are reportedly ditching ChatGPT for these AI rivals IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat OpenAI's first ChatGPT gadget could be a smart speaker with a camera ChatGPT spits out surprising insight in particle physics "Clavicular was mid jestergooning when a group of Foids came and spiked his Cortisol levels

What happens when the creator of Stack Overflow decides he's going to take on rural poverty with a guaranteed minimum income—and bankrolls it himself? Find out why Jeff Atwood believes AI and philanthropy might matter more to the American dream than any new software ever could. Hegseth gives Anthropic CEO until Friday to back down in AI safeguards fight Musk's xAI and Pentagon reach deal to use Grok in classified systems Anthropic Accuses Chinese Companies of Siphoning Data From Claude How will OpenAI compete? — Benedict Evans My first vibe coding project! Anthropic Links AI Agent With Tools for Investment Banking, HR THE 2028 GLOBAL INTELLIGENCE CRISIS QuitGPT is going viral — 700,000 users are reportedly ditching ChatGPT for these AI rivals IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat OpenAI's first ChatGPT gadget could be a smart speaker with a camera ChatGPT spits out surprising insight in particle physics "Clavicular was mid jestergooning when a group of Foids came and spiked his Cortisol levels

What happens when the creator of Stack Overflow decides he's going to take on rural poverty with a guaranteed minimum income—and bankrolls it himself? Find out why Jeff Atwood believes AI and philanthropy might matter more to the American dream than any new software ever could. Hegseth gives Anthropic CEO until Friday to back down in AI safeguards fight Musk's xAI and Pentagon reach deal to use Grok in classified systems Anthropic Accuses Chinese Companies of Siphoning Data From Claude How will OpenAI compete? — Benedict Evans My first vibe coding project! Anthropic Links AI Agent With Tools for Investment Banking, HR THE 2028 GLOBAL INTELLIGENCE CRISIS QuitGPT is going viral — 700,000 users are reportedly ditching ChatGPT for these AI rivals IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat OpenAI's first ChatGPT gadget could be a smart speaker with a camera ChatGPT spits out surprising insight in particle physics "Clavicular was mid jestergooning when a group of Foids came and spiked his Cortisol levels

Episode 484 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Godox LEDs and more at GodoxLEDusa.com - More mostly 20% OFF codes at LensShark.com/deals. Stories: This company thinks they've reimagined this. (#) Cosina's new Voightlander 40mm f/2. (#) Ricoh adds a useful feature to this popular camera. (#) Breaking down the Evoto controversy. (#) This body continues to dominate and for good reason. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

In today's episode I cover the history of Fujifilm from it's humble beginnings in 1934 to being an imaging and technology powerhouse today. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-494-the-history-of-fujifilm-19342026

Dombóvári Judittal beszélgettünk aki a fotózás mellett egy nagy divat magazin képszerkesztőjeként is dolgozott. Beszélgettünk business fotózásokról, megoldandó helyzetekről, fotós-fotóalany viszonyokról, esküvő fotózásról, arról, hogy milyen nőként jelen lenni egy fotózáson, és még sok másról.Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/165Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Judit instája:https://www.instagram.com/juditdombovari/- Judit esküvő fotós oldala:https://bohemelenses.com- Carson Coma fotózás:https://recorder.blog.hu/2020/12/04/_mar_masra_razzuk_a_seggunket_carson_coma-interju- Mako Szilveszter:https://www.instagram.com/szilvesztermako/- Jack Bridgland portfolio:https://jack-bridgland.format.com- Robert Pattinson by Jack Bridgland:https://circadianpictures.com/gq-robert-pattinson- Jack Bridgland mesél a fotózásról:https://youtu.be/RFxqFagHd0E?si=tjA_aPKia8TiLJw3

Kev and Neale are lamenting the weather: all hail weather-resistant lenses! Kev's also watching Mr Mercedes from behind the sofa - don't tell him the ending! On the show today, is Fujifilm mirrorless the perfect kit for newborn photography, when is the next FujiCast away day, and will Andreas like Kev's Valentine card enough that he invites The Mullins back into the inner fold? Kev shares why he released presets and Lightroom plugins and how they have changed his business, and why he still can't bear Apple kit! We also talk about third-party lenses and Neale sends Kev to sleep with some tech thoughts about podcasting. Email the show with your questions: click@fujicast.co.uk  For links go to the showpage. If you'd like to travel to far-off places with a camera: https://www.thejourneybeyond.uk/

Tényleg elég egy iPhone 2026-ban, vagy érdemes még milliókat ölni egy profi vázba? Gáborral kiveséztük a legfrissebb trendeket és segítünk dönteni!Megnézzük, hogy a mobilfotózás térnyerése mellett van-e még létjogosultsága a dedikált fényképezőgépeknek. Beszélünk a 27%-os magyar ÁFA okozta fájdalomról, a Fujifilm-hype-ról, és eláruljuk, melyik az a pont, ahol a technika már nem kifogás, hanem korlát.Ha épp kameravásárlás előtt állsz, vagy csak érdekel, merre tart a fotós világ 2026-ban, ez a videó neked szól!Ebben a részben:00:00 - Highlight és Intro (Az új kezdet)01:42 - Bevezető: Miért kérdezitek ennyien?02:26 - Mobil vs. Kamera: Hol a határ?08:58 - A legnagyobb hiba: Vázra vagy objektívre költs?19:48 - A magyar valóság: Árak és a 27% ÁFA32:53 - Profi igáslovak: Sony A7 IV és a többiek45:13 - A "Szerelemgép": Nikon Zf és a fotózás lelke57:23 - Összegzés: Mivel vágj bele 2026-ban?Csatlakozz a csatornatagok közé:https://www.youtube.com/channel/UCk4_upwPPBpMIJhnfdT2kbA/join✅ Iratkozz fel hogy ne maradj le a további tartalmainkról.https://www.youtube.com/channel/UCk4_upwPPBpMIJhnfdT2kbA?sub_confirmation=1Értesítünk e-mailben is az új podcast epizódokról: http://bit.ly/3qHoONu

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

Tether Tools makes the entire tethering workflow easy. From cables to accessories, everything is designed to work together right out of the box. But they also make workstations. Their new AeroTrac is a compact, lightweight workstation you can customize with accessories for your specific workflow. Built for photographers, it works just as well for audio, video, and podcasting setups. Check it out at tethertools.com/aerotracNow saving when you shop for your favorite gear at B&H Photo is even easier with the B&H Payboo Credit Card which lets you Save the Tax — you pay the tax, and B&H pays you back instantly! Terms apply, learn more at http://bhphoto.com/payboo. Credit card offers are subject to credit approval.Payboo Credit Card Accounts are issued by Comenity Capital BankA few weeks ago, Jordan Drake challenged Chris Niccolls and Jaron Schneider's historical camera pricing knowledge with a test: are cameras actually more expensive now than they were 10 or more years ago? The answer was mostly no, but it got them thinking... was the same the case for lenses? em>Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.In This Episode:00:00 - A very jetlagged intro14:52 - Despite Nikon's lawsuit, Viltrox says it isn't adjusting its product roadmap plans17:12 - OM System's new camera is an astro-focused OM-321:43 - Zeiss Aatma T1.5 primes are small, fast, and extremely expensive25:29 - Nikon posts huge losses27:59 - Fujifilm had record-high profits and Canon's camera business grew, too30:46 - Viltrox's first L-mount lens is the 16mm f/1.831:57 - Canon announced two new wide-angle lenses37:20 - Canon's new limited edition G7 X mark III looks great, but you'll probably never own one40:15 - Ricoh Pentax is releasing a limited edition camera strap made from recycled train seats42:59 - Are lenses actually more expensive now?1:03:50 - What have you been up to?1:08:30 - Check out the Exposure Festival in Calgary1:11:07 - Tech Support1:32:23 - Feel Good story of the week

Peti kiállításon járt. Gábor Canon eszközökben felfedezett kisebb-nagyobb észrevételekről és hibákról beszél. A Godox korrigálja a kör alakú vaku fényt. Business portré világításról beszélgetünk. Peti mesél arról, hogyan próbálta a led lámpával imitálni a napot. Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/164Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Tombor Zoltán kiállítás:https://capacenter.hu/kiallitasok/tombor-zoltan-lost-found/- Canon 45mm f/1.2 fókusz shift:https://youtu.be/GTqgSjeDF8k?si=7UzCsn2BNZilaVKZ&t=261- Canon R6II magától elsül back button fókusznál:https://youtu.be/L_Y5T32Y9ME?si=xoXW1wM6TbyhT9FF- Godox V1 Mid:https://www.godox.com/product-e/Flash/V1mid.html- Fstoppers vaku teszt:https://www.youtube.com/watch?v=Usj8ahCmbxs- Amaran Ray széria:https://www.unidomestore.hu/ez-itt-a-ray-szeria-118- Good Fortune film:https://www.imdb.com/title/tt27543578/

Photografix-News ist EUER News-Podcast rund um alle Themen der Digitalen Fotografie!

Episode 483 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - More mostly 20% OFF codes at LensShark.com/deals. Stories: A sports photography legend has passed. (#) Evoto controversy erupts. (#) Sony's a7 V cranks it up a notch. (#) This new 50mm f/1.2 is affordable. (#) No, this body hasn't been discontinued. (#) This contest is so super specific. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

This week, we celebrate the 100th episode of the CineD Focus Check show—a perfect opportunity to look back at the episodes that stood out and became truly special over time. It is also the right moment to thank our community. Your continued support, engagement, and passion for the show mean a great deal to us. We are genuinely grateful to have such a strong audience that shares our enthusiasm for filmmaking and the content we produce every week. In this milestone episode, we also cover a long-anticipated review. Johnnie shares his experience shooting with the FUJIFILM GFX ETERNA 55, along with insights and footage from a recent mini-documentary he shot using the camera. As always, Nino rounds things out with the latest weekly gear news. So hit play and enjoy our 100th episode of CineD Focus Check.   Chapters and Articles in This Episode (00:00) - Intro   (00:43) - Celebration of the 100th Episode and Recap   (30:27) - FUJIFILM GFX ETERNA 55 – First-Look Review & Mini Documentary https://www.cined.com/fujifilm-gfx-eterna-55-first-look-review-mini-documentary/   (58:03) - Behringer FLOW 4V – Compact Audio Mixer and Recorder for Filmmakers https://www.cined.com/behringer-flow-4v-compact-audio-mixer-and-recorder-for-filmmakers/   (01:02:22) - PrimeLight Design VoxBox Pro MK3 Announced – Support for Wide Lenses and Integrated Filtration https://www.cined.com/primelight-design-voxbox-pro-mk3-announced-support-for-wide-lenses-and-integrated-filtration/   (01:08:01) - Tilta Boulder Camera Cart XL Introduced – Carries up to 500kg of Gear https://www.cined.com/tilta-boulder-camera-cart-xl-introduced-carries-up-to-500kg-of-gear/   (01:11:48) - Call to Adventure in Different Films and How Characters Refuse to Hear It https://www.cined.com/call-to-adventure-in-different-films-and-how-characters-refuse-to-hear-it/   (01:14:11) - CINELUX REDUXA R2 Introduced – Focal Reducer for RED DSMC2 Cameras https://www.cined.com/cinelux-reduxa-r2-introduced-focal-reducer-for-red-dsmc2-cameras/   (01:20:01) - Google Veo 3.1 Ingredients to Video Update Adds Native Vertical Format, 4K Upscaling, and Enhanced Character Consistency https://www.cined.com/google-veo-3-1-ingredients-to-video-update-adds-native-vertical-format-4k-upscaling-and-enhanced-character-consistency/    (01:23:10) - Godox KNOWLED P600R Hard P4 and P1200R Hard P8 Announced – High-Output LED Panels with Multi-Zone Pixel Control   https://www.cined.com/godox-knowled-p600r-hard-p4-and-p1200r-hard-p8-announced-high-output-led-panels-with-multi-zone-pixel-control/   (01:26:40) - PolarPro CineFlow Filter Introduced – Adds Motion Effects In-Camera https://www.cined.com/polarpro-cineflow-filter-introduced-adds-motion-effects-in-camera/   (01:28:18) - Ruko U11MINI 4K Pocket-Sized Drone Introduced – Under 249 Grams, Dedicated Touchscreen Controller https://www.cined.com/ruko-u11mini-4k-pocket-sized-drone-introduced-under-249-grams-dedicated-touchscreen-controller/   (01:30:03) - Viltrox NexusFocus F1 Crowdfunding Campaign Launching Today – AI Autofocus for PL-Mount Lenses https://www.cined.com/viltrox-nexusfocus-f1-crowdfunding-campaign-launching-today-ai-autofocus-for-pl-mount-lenses/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Karácsony utáni pihenés, hóban fotózás, Gábort lefotózták, Peti led lámpákat próbálgat. Gábor mesél a 45mm f/1.2-ről. Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/163Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Pluribus:https://www.imdb.com/title/tt22202452/- LEGO NASA Apollo Saturn V:https://www.lego.com/en-hu/product/lego-nasa-apollo-saturn-v-92176- Lego Death Star:https://www.lego.com/en-hu/product/death-star-75419- Smallrig RF 10C:https://www.unidomestore.hu/smallrig-rf-10c-portable-focusable-led-video-light-4634-33427- Amaran Ray széria:https://www.unidomestore.hu/ez-itt-a-ray-szeria-118- Godox AK-R21:https://www.godox.com/product-b/AK-R21.html

Neale and Kev reminisce about driving tests; turns out Kev failed his a gazillion times! Also, firmware updates, what would the boys like to see improved in the near future on Fujifilm cameras, Kev sorts Neale's focus failures on the X100V, loaning out your cameras to family, and we ask whether the great Fujifilm zoom lenses can stand up to the quality offered by primes? We choose between particular cameras in the range, and we return to an ole' chestnut conversation; what NOT to do on Instagram, so a slight twist on the theme. Email the show with your questions: click@fujicast.co.uk  For links go to the showpage. If you'd like to travel to far-off places with a camera: https://www.thejourneybeyond.uk/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic phase shaping the industry, marked by scientific advancements, regulatory changes, and strategic shifts within major companies.Teva Pharmaceuticals is making significant strides under the leadership of CEO Richard Francis. The company is transitioning from its traditional focus on generic drugs to a more innovative biopharmaceutical approach. This strategic pivot aims to position Teva alongside industry giants in the biopharma sector, highlighting the increasing importance of innovation over generics in today's competitive landscape.Similarly, Fujifilm is enhancing its competitive edge by capitalizing on its biologics capacity. Rather than pursuing large mergers and acquisitions, Fujifilm is focusing on internal growth, underscoring a broader industry trend where companies are investing in organic growth and technological enhancements to maintain their market positions. This shift reflects a growing recognition of the value of leveraging unique facility designs and capabilities to boost production and efficiency.In regulatory news, the U.S. Food and Drug Administration (FDA) has mandated that pharmaceutical companies like Sanofi, GSK, AstraZeneca, and CSL include warnings about febrile seizures on flu vaccine labels. While these seizures are typically brief and harmless, transparent communication is crucial to maintain patient trust in vaccination programs. This regulatory update exemplifies the FDA's proactive efforts to enhance drug safety communications and address potential adverse effects associated with vaccines.The FDA has also issued untitled letters to Beone and ImmunityBio for promotional materials that potentially violated advertising guidelines. This action underscores the agency's vigilance in ensuring pharmaceutical marketing practices meet required standards of accuracy and transparency.Meanwhile, former Emergent BioSolutions CEO Robert Kramer faces insider trading allegations related to the sale of company shares before public disclosure of contamination issues at a production facility. This legal action brings to light ongoing scrutiny within the industry regarding corporate governance and ethical practices.In terms of advertising spending, AbbVie's Skyrizi topped annual TV ad spending charts for pharmaceuticals, closely followed by J&J's Tremfya. This highlights the continued emphasis on direct-to-consumer advertising as companies compete for market share in therapeutic areas.Internationally, companies like AbbVie are making strategic moves into emerging therapeutic spaces such as bispecific antibodies. AbbVie's recent deal to enter the PD-1xVEGF bispecific space signifies a growing interest in novel therapeutic modalities that offer potential breakthroughs in cancer treatment.At the policy level, former President Donald Trump announced "The Great Healthcare Plan," targeting insurance industry reforms and drug pricing. Although specifics remain sparse, this initiative reflects ongoing political discourse around healthcare affordability—a critical issue shaping industry strategies and public expectations.Turning our attention to Vedanta Biosciences, the company is reallocating resources toward its lead live bacteria cocktail program by significantly reducing its workforce. This move highlights growing interest in microbiome-based therapies as a novel approach to treating diseases by modulating gut microbiota. Vedanta's focus could have substantial implications for future therapeutic options, particularly in immune-related conditions.At the J.P. Morgan Healthcare Conference (JPM26), Chugai Pharmaceutical emphasized enhancing its recognition in the U.S. biopharma sector through new scientific avenues. This strategy underscores the importance of innovation and collaboration for Support the show

L'info du matin - Grégory Ascher et Erika Moulet ont parlé des objets dont on peut se séparer sans regret. Le winner du jour - Il interrompt un concert de rock, monte sur scène et demande sa petite amie en mariage. - Elle ouvre un œil en pleine nuit et croit caresser son chien sur son lit. Le flashback du jour - Mars 1996 : "Spaceman", premier single de Babylon Zoo, devient rapidement numéro 1 dans plusieurs pays d'Europe dont la France. - Au même moment, les salles de cinéma françaises se remplissent pour découvrir "Toy Story", premier film d'animation des studios Pixar. Les savoirs inutiles - Le transat ne vient pas des plages mais des ponts des grands paquebots transatlantiques, à la fin du XIXe siècle. La chanson du jour - OMC "How Bizarre". 3 choses à savoir sur Janis Joplin Qu'est-ce qu'on teste ? - Fujifilm présente un appareil photo instantané au look rétro, l'Instax Mini Evo Cinema, pensé comme un voyage dans le temps. Le jeu surprise (Ni oui ni non) - Virginie de Bréhand, vers Saint-Brieuc, gagne un séjour pour quatre personnes dans une résidence Pierre & Vacances. La Banque RTL2 - Morgane de Civray-de-Touraine, vers Tours, gagne 400 €. - Amandine de Sammeron, vers Meaux, gagne un bon d'achat de 500 € valable sur le site Fabrique de Style. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

This week's episode dives into Apple's newly announced Creator Studio – now offered as a subscription model. Johnnie and Nino also take a closer look at the rise and fall of Vimeo, discussing what changed over the years on this once filmmaker-focused platform. Plus, FUJIFILM has announced a… let's say, very unique cinema camera. So don't miss out on the latest updates from the world of cine tech! Chapters and Articles in This Episode (00:00) - Intro (01:37) - Recent Podcast Episode: https://www.cined.com/podcast/ (07:35) - Episode topics overview (12:30)- Apple Creator Studio Announced – Final Cut Pro, Logic Pro, Pixelmator Pro & More Subscription Bundle With AI Editing and Generative Tools https://www.cined.com/apple-creator-studio-announced-final-cut-pro-logic-pro-pixelmator-pro-more-subscription-bundle-with-ai-editing-and-generative-tools/ Apple Creator Studio: CineD Exclusive Interview Reveals the Future of Pro Apps & Licensing https://www.cined.com/apple-creator-studio-cined-exclusive-interview-reveals-the-future-of-pro-apps-licensing/ (36:56) - How Vimeo Betrayed the Filmmakers Who Built It https://www.cined.com/how-vimeo-betrayed-the-filmmakers-who-built-it/ (49:24) - GOA – An Indian Wildlife Documentary – Shot on PIXBOOM Spark and LUMIX Cameras https://www.cined.com/goa-an-indian-wildlife-documentary-shot-on-pixboom-spark-and-lumix-cameras/ (54:38) - FUJIFILM Instax Mini Evo Cinema Launched with Built-in Printer https://www.cined.com/fujifilm-launches-the-instax-mini-evo-cinema-camera-with-built-in-printer/ (01:01:43) - Poll: Mobile Filmmaking – What Would It Take for You to Move From iPhone to Android Device? https://www.cined.com/poll-mobile-filmmaking-what-would-it-take-for-you-to-move-from-iphone-to-android-device/ (01:13:50) - MID49 Direct Connect XLR Module for FUJIFILM GFX ETERNA 55 – Lower Profile, Two-Channel Balanced Audio https://www.cined.com/mid49-direct-connect-xlr-module-for-fujifilm-gfx-eterna-55-lower-profile-two-channel-balanced-audio/ (01:17:54) - GoPro and ASUS Launch Co-Branded Creator Laptop – Workflow Integration or Marketing Exercise? https://www.cined.com/gopro-and-asus-launch-co-branded-creator-laptop-workflow-integration-or-marketing-exercise/ (01:24:30) - ARRI Reaffirms Commitment to Lighting and Camera Systems – Full Roadmap for 2026, Munich Consolidation Underway https://www.cined.com/arri-reaffirms-commitment-to-lighting-and-camera-systems-full-roadmap-for-2026-munich-consolidation-underway/ (01:27:31) - Hohem iSteady MT3 Gimbal Series & Company's First Portable SSD-001 Released https://www.cined.com/hohem-isteady-mt3-gimbal-series-companys-first-portable-ssd-001-released/ (01:32:44) - Talking About “Lens Character”, Finding the Right Words – a Video Series by Tito Ferradans https://www.cined.com/talking-about-lens-character-finding-the-right-words-a-video-series-by-tito-ferradans/ (01:35:08) - Extreme Wide Shots for Impactful Storytelling – With Film Examples https://www.cined.com/extreme-wide-shots-for-impactful-storytelling-with-film-examples/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

With a PetaPixel Membership, not only can you support original PetaPixel reporting and in-depth reviews, but you can also remove ads from the website and gain access to some seriously great perks, too. Members get $15 off the Moment Store, 5% off certified pre-owned gear from KEH, 25% off the PetaPixel Merch Store, and now can download full-resolution RAW files and JPEGs from the latest cameras and lenses. It costs just $3 per month or $30 per year. Join today: https://petapixel.com/members/This week on The PetaPixel Podcast, Chris Niccolls, Jordan Drake, and Jaron Schneider are joined by Sarah Teng to talk about the Instax Mini Evo Cinema. And, in a weird bizzaro world twist, it's Chris who has to convince Sarah that it's great. She's not sold, but Chris absolutely loves this weirdo video/printer/instant camera hybrid. Also, the Ricoh GR IV Monochrome finally has a price and release date, but it's a lot more expensive than the base model. Apple launched a new suite of creative apps called the Creator Studio, Adorama was literally giving X half cameras away, and you can get a GoPro-branded laptop for some reason. Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode:00:00 - Intro, and Sarah Teng is back!12:11 - The Ricoh GR Monochrome costs $700 more than the base model16:32 - Fujifilm is releasing an all-white X half in China17:52 - Meanwhile, Adorama is literally giving X halfs away20:33 - Pentax isn't sure how to make the DSLR popular again26:43 - You can get a GoPro laptop, if you're into that30:56 - Nikon's 24-105mm f/4-7.1 is a new kit zoom for the Z5 II32:57 - The OM-D E-M10 Mark IV isn't being discontinued36:20 - Apple Creator Studio is the long-awaited competitor to Adobe Creative Cloud44:15 - Is the Mini Evo Cinema the best Instax camera ever?1:03:54 - What have you been up to?1:10:10 - Tech support1:16:28 - Feel good story of the week: Don't ever change, Radio Shack

A snack of the year is showing itself a bit early, John has some consumer advice, and Robb peddles his wares. There is hope for January after all: Oreo is launching a Crème Egg flavoured biscuit Heinz Dipper Beats Studio Pro AirPods Max MacStories Deals (@MacStoriesDeals@macstories.net) The newest Fujifilm compact camera “time-travels” with an Eras Dial and a design inspired by 1960s 8mm cine cameras. But, there's a catch Pens, Inks, and Obsidian Bases Robb's Sticker Shop

A Inteligência Artificial Generativa chegou a um ponto onde distinguir o real do falso é praticamente impossível. Em 2026, robôs fotógrafos já são atrações principais em feiras globais e a perfeição técnica tornou-se uma commodity barata.Neste cenário de caos tecnológico, a maior tendência para fotógrafos em 2026 é exatamente o oposto do que a tecnologia oferece: a busca radical pelo imperfeito, pelo humano e pelo real.Neste episódio do C.A.O.S. Fotográfico, vamos decodificar porque a "estética da imperfeição" é o seu maior ativo estratégico para sair na frente e transformar a ameaça da IA na sua maior oportunidade de negócio este ano.Confira as mais lidas da semana aqui: https://www.enfbyleosaldanha.com/post/mais-lidas-fotografia-robo-ces-estetica-imperfeita-2026O que você vai descobrir neste episódio:Reflexão do Dia do Fotógrafo: Por que 2026 exige que você deixe de ser um "clicador" para se tornar um estrategista visual em um mundo saturado por IA.A Estética da Imperfeição: Entenda a contatendência global onde o "estranho" e o "cru" valem mais que a perfeição plástica dos algoritmos.A Visão das Big Techs: O que a direção das grandes redes sociais (como Instagram) sinaliza sobre o erro de focar apenas em perfeição técnica.O Fim do "Ver para Crer": Como a saturação de imagens falsas gerou uma crise de confiança e por que marcas estão sendo rejeitadas por parecerem artificiais demais.Robôs vs. Humanos: A evolução dos robôs fotógrafos na CES e o que isso realmente significa para o futuro dos serviços fotográficos manuais.O Renascimento Analógico: Inovações da Fujifilm e o crescimento explosivo da demanda por filme e impressão instantânea como resposta à digitalização excessiva.Onde Está o Dinheiro em 2026: O potencial inexplorado na fotografia esportiva, eventos sociais e parcerias estratégicas com o setor de turismo e hotelaria.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

CES 2026 brought notable innovations for filmmakers and media professionals. In this episode, we break down the most interesting tech: Fujifilm's new instax mini Evo Cinema Camera with vintage film emulation, LEGO's impressive computer-integrated Smart Brick, HP's EliteBoard keyboard computer, Boston Dynamics' fully electric Atlas robot, Samsung's thin 3D display technology, and Nvidia's Rubin platform advances. --The views and opinions expressed in this podcast are the personal views of the hosts and do not necessarily reflect the views or positions of their respective employers or organizations. This show is independently produced by VP Land without the use of any outside company resources, confidential information, or affiliations.

In this week's episode, Copyright Tests, Fake Kodak CFExpress cards, Ricoh talks about their GR Series and Fujifilm has a new video capable Instax Evo camera. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-488-copyright-test-fake-kodak-cards-ricoh-gr-series

Leeds United produced a defensive masterclass against the billion pound squad of the premier league champions Liverpool. With Rodon out injured Farke rolled the dice on several fringe players who played their part to earn a great point prolonging Leeds' unbeaten run to 6 matches.

In case you didn't already know, 2025 marks 10 years since we started the B&H Photography Podcast, making today's show our tenth annual Photo Gear of the Year episode! A lot of cameras have come down the pike since that first recap, along with a veritable roller coaster of marketing strategies and photographic trends. To follow up on a trend discussed last year, we start out with a nod to point-and-shoots, a craze that, according to Kevin, has "become fever pitch." To expand on this theme, we look back in time to when digital point-and-shoots were losing ground to the ubiquitous camera phone, leading to Mike's theory that the current digicam trend is "real nostalgia for mid-aughts frivolity." We also point to a multi-tiered strategy among manufacturers, allowing them to cater to different user bases—from vloggers to professionals to hybrid shooters to the all-important enthusiast market. This lighthearted banter leads into our main course, focused on new releases from Canon, FUJIFILM, Godox, Hasselblad, Leica, Nikon, OM SYSTEM, Panasonic, Peak Design, Ricoh Pentax, Sigma, and Sony. Finally, in addition to predictions for 2026, we wrap things up with Kevin's picks for travel-friendly photo accessories to catch his eye this year. Stay to the end to learn about Peak Design's latest travel bags and tripods, plus the innovative modular design behind a new flash system from Godox. Guest: Kevin Rickert Episode Timeline 2:50: Kevin looks back at recent camera trends, and identifies separate tiers for vlogging, high resolution cameras, hybrid cameras, and the nostalgia for old point & shoots. 9:11: Canon releases: R50 V, R6 Mark III, Powershot V1… plus a nod to the older G7 X Mark III 18:00: FUJIFILM releases: X-half digital camera, X-E5, X-T30 III, GFX100RF, Instax Wide EVO 33:10: Hasselblad release: X2D II 100C 37:37: Leica releases: M EV1, Q3 Monochrome, SL3-S, SL3 Reporter 43:30: Episode break 43:52: Nikon releases: ZR 6K, Z5 II, and a Z6 III firmware update 54:22: OM SYSTEMS releases: OM-3, OM-5 MK II 57:38: Panasonic releases: S1R II, S1 II, S1 IIE 1:02:48: Ricoh release: GR IV 1:05:40: Sigma release: BF Mirrorless 1:09:48: Sony releases: RX1R III, FX3A, FX2, a7 V 1:23:50: Kevin's recommendation for a better editing workflow when travelling with an Apple iPad Pro 1:26:06: Peak Design releases: Roller Pro Carry-On & Pro Carbon Fiber Tripods with Ball Head 1:28:45: Godox release: iT-32 TTL Mini Flash system 1:30:12: Revisiting the current point and-shoot craze and the digicam look 1:34:52: Kevin's upcoming travel plans, and thinking ahead for the total eclipse in mid-August 2026 1:39:00: Kevin, Derek, and Mike share their predictions for 2026 Guest Bio: Kevin Rickert is B&H Photo's Senior Sales Trainer for Photography and Lighting. It's Kevin's job to keep in touch with camera and lens manufacturers and get details about all the latest releases and updates. His role is to make sure the world-renowned B&H staff has all the information to answer your who, what, why, and other questions that you may ask, so they can satisfy all your wants and needs. Born and raised in New York, Kevin is an intrepid street photographer, an avid traveler, and a baseball fan with 23 years in electronic retail, the last 11 of which have been spent as a sales trainer at B&H. Stay Connected: B&H Photo Video Website: https://www.bhphotovideo.com B&H Photography Podcast landing page: https://www.bhphotovideo.com/explora/podcasts B&H Photography Podcast on B&H Photo's YouTube channel: https://www.youtube.com/@BandH/podcasts  B&H Photo Video Instagram: https://www.instagram.com/bhphoto B&H Photo Video Twitter: https://twitter.com/bhphoto  Credits: Host: Derek Fahsbender Senior Creative Producer: Jill Waterman Senior Technical Producer: Mike Weinstein Executive Producer: Richard Stevens  

Episode 482 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - More mostly 20% OFF codes at LensShark.com/deals. Stories: Lensrentals annual list is pretty telling. (#) Leica drops some significant updates. (#) This new fisheye busts the funk in a new way. (#) The Viltrox 35mm f/1.2 LAB should be great as well. (#) This show turns 11!   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Do you ever get tired of manually searching for, organizing, and culling your images? We do, too, and that's where Excire can help!Excire's photo-management software harnesses AI to make tedious tasks 10x faster, easier, and more fun. Thanks to Excire, you can easily get your images organized, stay on top of culling, and instantly find any photo in your catalog—so you can spend less time managing your images and more time doing what you love! And since the AI runs locally on your computer, you'll never have to worry about privacy or security. Best of all, Excire can be integrated seamlessly into your current workflow, either using the standalone image organizer, Excire Foto 2025, or the Lightroom Classic plugin, Excire Search 2026. To purchase an Excire lifetime license or to download a 14-day free trial, visit http://excire.com/en/shop/! PetaPixel viewers can receive 15% off their purchase with the special discount code PETAPIXEL.Surprise! The PetaPixel Podcast team got together one more time for the true Season 4 finale! Grab a glass of eggnog, don your Santa hats, and pull the pole out from the crawlspace, because it's time for the annual airing of grievances!Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode00:00 - Intro (Your most vivid Christmas memory)13:53 - DJI drones have been banned in the US16:30 - Fujifilm to spend nearly $32 million expanding Instax film production20:18 - Benro's electronics Variable ND filter automatically adjusts its strength24:56 - Leica made major updates to the SL3 and Q3 series autofocus26:48 - All visual arts students worldwide can now join ASMP for free27:50 - Ricoh's GR IV HDF is coming soon and has a new electronic shutter31:56 - The Annual Airing of Grievances52:51 - What have you been up to?58:52 - Tech Support

A karácsonyi szellemet még nem érezzük annyira, az év végét viszont már igen. Rendezvényeket fotóztunk, Peti majdnem modellt fotózott, de elmesélte a hozzá tartozó tanulságos történetet. Gábor pedig ismét egy erősen technikai problémára akadt a Godox vakukkal kapcsolatban.Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/162Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Reflectlens:https://reflectlens.com- Godox V100:https://www.godox.com/product-b/Flash/V100.html- Canon EL-5:https://www.canon.hu/cameras/speedlite-flash-el-5/- Canon ST-E10:https://www.canon.hu/cameras/speedlite-transmitter-st-e10/- Kör alakú vs. négyzet alakú vaku:https://jeff-fried.com/wp-content/uploads/2024/03/Circular-Head-vs-Rectangle-Head.jpg- Lego Technic #42128 Nagy teherbírású vontató:https://www.lego.com/hu-hu/product/heavy-duty-tow-truck-42128

We look back at Fujifilm for 2025 and talk about the hits, the road bumps and so much more. Fred Ranger joins us to discuss this most interesting year! Follow Fred Ranger ------------------------ YouTube: https://www.youtube.com/c/FredRanger IG: https://www.instagram.com/fredranger/?hl=en Web: https://fredranger.com/ Email the Show: FujiLoveFeedback@gmail.com Follow Marc Sadowski: ------------------------ Substack: https://substack.com/@thefilmish IG: https://www.instagram.com/marcsadowski/ Twitter: https://x.com/marcsadowski YouTube: https://www.youtube.com/@film-ish

Its here! ThisWeekInGeek's annual Holiday Gift Guide for 2025!Mike The Birdman & Alex The Producer share their picks and discuss why they make great gifts. TWIG Crew members Ken and JT pop in to give a few picks of their own as well! So come join us for a great mix of gift ideas!This year we have a lot of gift ideas to share so we are including a link to a PDF list of our picks with direct links to each so you can have easy access. Think of it like a Christmas list from when you were a kid!Feel free to download a PDF of the guide links: https://www.dropbox.com/scl/fi/9o6s3idhj8f2rkddyfs5t/TWIG-2025-Holiday-Gift-Guide-Show-Notes-Links.pdf?rlkey=be7rtmgran7jou69eqe9ii8db&st=3pgzwtop&dl=0Thanks to all the great companies and people that sent us items for review and gift guide consideration!Show Notes:Your Geekmasters:Mike "The Birdman" - https://bsky.app/profile/birdmanguelph.bsky.socialAlex "The Producer" - https://bsky.app/profile/dethphasetwig.bsky.socialFeedback for the show?:Email: feedback@thisweekingeek.netTwitter: https://twitter.com/thisweekingeekBluesky: https://bsky.app/profile/thisweekingeek.netSubscribe to our feed: https://www.spreaker.com/show/3571037/episodes/feediTunes: https://podcasts.apple.com/us/podcast/this-week-in-geek/id215643675Spotify: https://open.spotify.com/show/3Lit2bzebJXMTIv7j7fkqqWebsite: https://www.thisweekingeek.netDecember 8, 2025

Episode 481 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Big savings at participating retailers and at Calibrite.com. - Save 20% at BenroUSA.com with code SHARKY2025. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Sony releases firmware updates…then pulls one. (#) This super fast 50 is fairly affordable. (#) This new tool is useful, but so are these. (#) (#) (#) The Laowa 35mm f/2.8 Zero-D Tilt-Shift .5x Macro. (#) Dynamic range in this body is excellent. (#) A retro lens clearly inspired by a classic from the past. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Aisha Schliessler is a writer and director based in Los Angeles and London. A third-generation filmmaker, life behind the camera is in her blood. As a narrative director, Aisha is passionate about exploring the human psyche through a nuanced and stylistic lens. Her work emphasizes character and emotional storytelling, often infused with playfulness and irony. A love of architecture, fashion, and photography serves as a throughline in her work, as she strives to craft visually compelling worlds for her characters to inhabit. Drawing from her background in acting, Aisha brings a thoughtful, compassionate approach to working with talent and guiding performance. Her work spans a wide range of projects and has been featured on platforms such as Free The Work, Booooooom TV, Girls in Film, NoBudge, and Film Shortage. Her short film RHINESTONE BLUE, made in collaboration with Fujifilm, screened at several recognized festivals, including the Vail Film Festival, Beverly Hills Film Festival, and Idyllwild International Festival of Cinema. The film earned a Telly Award, a Cannes Corporate Media & TV Award, and multiple festival honors, including Best Short. Other notable projects include the short film THE CALL, starring Juno Temple, and most recently, the short documentary A GREAT LOVE, profiling the acclaimed equine sculptor, Charlie Langton. She is currently in development on her first feature film. Topics Discussed In This Episode: How Aisha got started directing films (00:03:09) Her film A Great Love (00:10:58) Being present in the journey (00:17:49) Aisha speaks about her process in filmmaking (00:24:15) Yoshino and Aisha speak about the process of acting and directing (00:32:26)  Exploring subjectivity in art (00:48:46) Leaning into one's authenticity (00:56:34) artistdecoded.com aishaschliessler.com instagram.com/aishaschliessler

Stand well back from the podcast player today, because Kev's brought man flu to the airwaves! What he needs is a week-long retreat in Scotland, which Neale shares details about during the show. Today, photographic mishaps, when things don't quite work out as you plan, post professional gig rituals, wedding fair conversions, and we ask the question, are engagement shoots a thing anymore? Also, Ed Sheeran's One Shot show, using flash for nature photography, faster Fujifilm lenses for landscape photography, expanding your photo business into social photography, being genre-specific on a website, photographing weddings for free to gain experience, and marketing to new clients. Email the show with your questions: click@fujicast.co.uk  For links go to the showpage. If you'd like to travel to far-off places with a camera: https://www.thejourneybeyond.uk/

Send us a textIn this episode of the SheClicks Women in Photography Podcast, host Angela Nicholson is joined by British street photographer Dawn Eagleton, who has built a strong reputation for her honest and captivating street portraits. Dawn's approach is rooted in connection, authenticity and quiet confidence, making her images not only visually compelling but emotionally resonant.Dawn shares how she first discovered her passion for photographing people candidly in public spaces and how her instincts led her towards a style defined by raw, unposed portraits. Throughout the conversation, she talks about how she overcame the fear of photographing strangers, the subtle cues she uses to read body language and why respectful interaction is often more powerful than asking for permission.As Angela and Dawn explore the challenges and rewards of street portraiture, they also discuss the importance of eye contact, how to capture people in their natural state and how Dawn built up the courage to approach subjects in a calm and open way. Her thoughts on authenticity, presence and emotional awareness offer helpful insights for any photographer looking to work more confidently in public.Later in the episode, Dawn shares the story behind her first self-published book Through the Glass, a collection of portraits taken through windows that reflect both physical distance and emotional proximity.This episode is a must-listen for anyone curious about street photography, looking to build confidence behind the lens, or interested in photographing people in a more honest and respectful way.Connect with DawnWebsiteInstagramFacebookTakeawaysConfidence grows with practice – street photography becomes easier the more you face the initial discomfort and keep shooting.Authenticity matters – unposed, candid moments can tell more powerful stories than staged portraits.Connection is key – a small gesture like a smile or nod can create mutual understanding and respect.Learn to read body language – understanding how people react helps you decide when to photograph or walk away.Your presence affects the picture – how you carry yourself influences how your subject responds, even if they don't notice you at first.Photography is more than the image – it's also about the moment, the experience and the personal growth that comes with it.FujifilmThis podcast is supported by Fujifilm, one of the best-known photography brands in the world. Fujifilm's award-winning X Series and GFX system cameras and lenses are suitable for all types of photographers and videographers. Each has been developed utilising the experience gained from more than 90 years in the industry, featuring unique film simulation modes that everyone knows and loves.Support the show

Do you ever get tired of manually searching for, organizing, and culling your images? Excire's photo-management software harnesses AI to make tedious tasks 10x faster, easier, and more fun. To purchase an Excire lifetime license or to download a 14-day free trial, visit http://www.excire.com/en/shop! EXCIRE BLACK FRIDAY SALE: PetaPixel viewers can receive 30% off their purchase with the special discount code PETAPIXEL30 -- valid through December 7th!Now saving when you shop for your favorite gear at B&H Photo is even easier with the B&H Payboo Credit Card, which lets you Save the Tax — you pay the tax, and B&H pays you back instantly! (Save the Tax on eligible purchases shipped to eligible states.) Or you can pay over time with 6 and 12 month financing (on minimum purchases of $199 for 6 months, and $599 for 12 months). Terms apply, learn more at http://bhphoto.com/payboo.Credit card offers are subject to credit approval. Payboo Credit Card Accounts are issued by Comenity Capital Bank.Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode00:00 - Intro08:37 - The Kodak Snapic A1 is a $99 film camera with a double exposure switch11:06 - The AP has switched to DaVinci Resolve12:29 - Arri closed two facilities dedicated to lighting16:12 - Leica's M EV1 is finally available in the US after delays due to the government shutdown17:15 - Q3 Monochrom was announced22:41 - Lumix significantly improved S1 II and S1R II record times25:27 - Laowa made a new half-macro tilt shift lens28:36 - Fujifilm teamed up with a Japanese artist for a limited edition GFX100RF31:35 - The world's biggest walk-in camera is for sale34:38 - "The Stringer" Utterly Ruins the Reputation of Nick Ut and the AP1:29:12 - Read Matt's review of "The Stringer" on PetaPixel1:29:24 - While you were out taking pictures, Polar Pro studied the blade

Why does success often feel like a moving target? In this episode, we explore the highs and lows of the creative journey, from embarrassing shoot stories and drone disasters to the mindset shifts that keep us as photographers inspired. Expect honest reflections on the pressures of social media, the pursuit of passion over perfection, and why the creative process never truly gets easier.Expect to Learn:Why reaching milestones doesn't always bring the satisfaction you expectHow to stay true to your creative valuesWhy reaching a new level in your craft often feels normal or underwhelmingHow to protect your love for photography by setting boundariesSponsors:Thanks to Tamron for sponsoring this episode! Their Holiday Instant Savings are here! Save up to $300 on select lenses for Sony, Nikon, and FUJIFILM mirrorless cameras now through January 11th, 2026. Explore here at www.tamron-americas.com Thanks also to the National Park Foundation for sponsoring today's episode. Enter the Share the Experience photo contest for a chance to win $10,000 and prizes from Celestron, Historic Hotels of America, and YETI. The grand prize winner's photo could be featured on the America the Beautiful—the National Parks and Federal Recreational Lands Annual Pass. The deadline to submit is December 31st 2025!Submit your best shots now at sharetheexperience.org/tpmOur Links:Join our subreddit where you can share stories and ask questions:https://www.reddit.com/r/photographermindset/Subscribe to TPM's Youtube page and watch full length episodes: https://www.youtube.com/thephotographermindset/Make a donation via PayPal for any amount you feel is equal to the value you receive from our podcast episodes! Donations help with the fees related to hosting the show:https://paypal.me/podcasttpm?country.x=CA&locale.x=en_USThanks for listening!Go get shooting, go get editing, and stay focused.@sethmacey@mantis_photography@thephotographermindsetSupport the show

The holiday season is here, and so is OM SYSTEM's Black Friday pricing. Right now, you can save up to $400 on many of the cameras and lenses that they make.The OM-1 Mark II, their professional powerhouse perfect for bird and wildlife photography, with blazing-fast autofocus and class-leading stabilization, is $400 off. For those looking for an even lighter all-around travel kit, the OM-3 and M.Zuiko 12-45mm F4.0 PRO package is only $2099.99. And if you're looking to upgrade your glass, you'll find big savings on almost al M.Zuikol lenses.Check out the full lineup at explore.omsystem.com/petapixel and take your photography to the next level without breaking the bank.Now saving when you shop for your favorite gear at B&H Photo is even easier with the B&H Payboo Credit Card, which lets you Save the Tax — you pay the tax, and B&H pays you back instantly! (Save the Tax on eligible purchases shipped to eligible states.) Or you can pay over time with 6 and 12 month financing (on minimum purchases of $199 for 6 months, and $599 for 12 months). Terms apply, learn more at http://bhphoto.com/payboo.Credit card offers are subject to credit approval. Payboo Credit Card Accounts are issued by Comenity Capital Bank.The PetaPixel team uses different cameras and lenses every day as part of our job but behind the scenes, we carry around a few pieces of mainstay gear that we just can't live without. This week, The PetaPixel Podcast team reveals the equipment they've been carrying this year that keeps the wheels of journalism turning. We use Riverside to record The PetaPixel Podcast in our online recording studioIn This Episode00:00 - Intro; Chris and Jordan are working a shift at the Camera Store Next Week!12:25 - We just got the best look yet at Jeff Bridges' WideluxX project15:10 - ARRI is trying to mimic film with a digital plugin18:11 - Fujifilm released the film simulation LUTS it promised20:49 - Light Lens Lab has recreated the Leica Summilux 35mm f/1.424:56 - Mint addresses major Rollei 35AF shortcoming27:40 - Lumix is shutting down its pro services in the UK and Europe31:34 - The R6 Mark III can overheat34:34 - Basketball player runs back onto the court with camera strapped to his leg36:51 - Everything ELSE you missed!41:00 - The Fantasy Camera Draft poll results44:46 - Do you do graphic design? Reach out!45:54 - The gear we use every day (2025 edition)1:07:49 - Chris teases an upcoming new Wotancraft Pilot sling bag1:11:22 - New segment alert: Review Roundup!1:19:51 - What have you been up to?1:23:58 - Tech support1:35-45 - Feel good story of the week

Episode 480 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Save 20% at Tenba.com with code SHARKY2025. - Save 20% at BenroUSA.com with code SHARKY2025. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Nextorage cards do double duty for the first time. (#) Canon is having trouble keep up with demand. (#) Meike's new 85mm is affordable. (#) Lexar goes even bigger, but better? (#) This new 28 is fast! (#) Leica found a way to make them even more expensive. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

In this episode, we dive into the art of landing photography clients with guest Dalton Johnson (@storiesbydalton), a full-time commercial and editorial photographer known for his outdoor and adventure work. Dalton shares his insights on balancing inbound and outbound strategies, building genuine relationships, and creating systems that attract work. Whether you're a full-time photographer or balancing a side hustle, this conversation is packed with actionable tips to help you connect with clients, stay top of mind, and create a sustainable career.Expect to Learn: The difference between pitching clients directly and building systems that attract them to youWhy fostering long-term connections with potential clients can lead to consistent workHow to use social media effectively without getting caught in the "posting for the algorithm" trapHow to use your portfolio to showcase your capabilities to potential clientsHow to maintain subtle, meaningful outreach that keeps you on a client's radar without being pushyDalton's Website: https://dalton-johnson.com/Dalton's YouTube: https://www.youtube.com/@storiesbydaltonSponsors:Thanks to Tamron for sponsoring this episode! Their Holiday Instant Savings are here! Save up to $300 on select lenses for Sony, Nikon, and FUJIFILM mirrorless cameras now through January 11th, 2026. Explore here at www.tamron-americas.com Thanks to the National Park Foundation for sponsoring today's episode. Enter the Share the Experience photo contest for a chance to win $10,000 and prizes from Celestron, Historic Hotels of America, and YETI. The grand prize winner's photo could be featured on the America the Beautiful—the National Parks and Federal Recreational Lands Annual Pass. Submit your best shots now at sharetheexperience.org/tpmOur Links:Join our subreddit where you can share stories and ask questions:https://www.reddit.com/r/photographermindset/Subscribe to TPM's Youtube page and watch full length episodes: https://www.youtube.com/thephotographermindset/Make a donation via PayPal for any amount you feel is equal to the value you receive from our podcast episodes! Donations help with the fees related to hosting the show: https://paypal.me/podcasttpm?country.x=CA&locale.x=en_USThanks for listening!Go get shooting, go get editing, and stay focused.@sethmacey@mantis_photography@thephotographermindsetSupport the show

Episode 479 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Big savings on Accsoon gear at AccsoonUSA.com and participating retailers. - Benro's Fall Sale at BenroUSA.com and participating retailers. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Canon's R6 Mark III could be Camera of the Year. (#) This fast 45 is more affordable. (#) Fujifilm's X-T30 III ups the game. (#) The XC 13-33mm f/3.5-6.3 is the smallest. (#) Capture One adds these, but is it enough? (#) It's kinda a rangefinder, but kinda not at the same time. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Episode 478 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Big savings on Accsoon gear at AccsoonUSA.com and participating retailers. - Benro's Fall Sale at BenroUSA.com and participating retailers. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Nikon fleshes out the lineup with two new lenses. (#) CRDBAG makes more space in your bag with these. (#) Viltrox's new 50mm f/1.4 PRO is affordable. (#) Venus Optics can't possibly be making much with this 200. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Episode 477 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Calibrate Photo Kit. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Karens are gonna Karen. (#) CPIA's numbers and the summer slump. (#) Nikon says this isn't true. (#) This Tamron lens rounds out the G2 Trinity. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).